

Cristina Sierra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5683784/publications.pdf>

Version: 2024-02-01

59
papers

1,649
citations

257450

24
h-index

302126

39
g-index

66
all docs

66
docs citations

66
times ranked

2275
citing authors

#	ARTICLE	IF	CITATIONS
1	Efecto de una intervención educativa repetida frente a una intervención inicial sobre el control de la presión arterial en pacientes hipertensos. Medicina Clínica, 2022, 158, 406-412.	0.6	0
2	Is there sufficient evidence to justify changes in dietary habits in heart failure patients? A systematic review. Korean Journal of Internal Medicine, 2022, 37, 37-47.	1.7	4
3	The Role of Arterial Stiffness in the Estimation of Cardiovascular Risk in Liver Transplant Recipients. Transplantation Direct, 2022, 8, e1272.	1.6	4
4	Routine assessment of cognitive function in older patients with hypertension seen by primary care physicians: why and how? a decision-making support from the working group on "hypertension and the brain" of the European Society of Hypertension and from the European Geriatric Medicine Society. Journal of Hypertension, 2021, 39, 90-100.	0.5	30
5	Grado de conocimiento de la hipertensión en pacientes hipertensos. Enfermería Clínica, 2020, 30, 99-107.	0.3	6
6	Hypertension and the Risk of Dementia. Frontiers in Cardiovascular Medicine, 2020, 7, 5.	2.4	90
7	Blood pressure in acute ischemic stroke. Journal of Hypertension, 2018, 36, 1212-1221.	0.5	21
8	Obesity and cardiovascular risk. Journal of Hypertension, 2018, 36, 1427-1440.	0.5	86
9	Obesity and cardiovascular risk. Journal of Hypertension, 2018, 36, 1441-1455.	0.5	44
10	Central blood pressure variability is increased in hypertensive patients with target organ damage. Journal of Clinical Hypertension, 2018, 20, 266-272.	2.0	10
11	Misdiagnosis of resistant hypertension: Real frequency of true resistant hypertension in patients with suspected resistance to treatment. Medicina Clínica (English Edition), 2018, 150, 20-23.	0.2	0
12	Body Composition and Circulating Polyunsaturated Fatty Acids at Age 6 Years: A Longitudinal Pilot Study. Hormone Research in Paediatrics, 2018, 90, 414-418.	1.8	0
13	Association of Either Left Ventricular Hypertrophy or Diastolic Dysfunction With 24-Hour Central and Peripheral Blood Pressure. American Journal of Hypertension, 2018, 31, 1293-1299.	2.0	11
14	High blood pressure, Alzheimer disease and antihypertensive treatment. Panminerva Medica, 2018, 60, 8-16.	0.8	20
15	Twenty-four-hour central blood pressure is not better associated with hypertensive target organ damage than 24-h peripheral blood pressure. Journal of Hypertension, 2017, 35, 2000-2005.	0.5	23
16	Cuff-Based Oscillometric Central and Brachial Blood Pressures Obtained Through ABPM are Similarly Associated with Renal Organ Damage in Arterial Hypertension. Kidney and Blood Pressure Research, 2017, 42, 1068-1077.	2.0	10
17	Towards new recommendations to reduce the burden of alcohol-induced hypertension in the European Union. BMC Medicine, 2017, 15, 173.	5.5	24
18	Can the Treatment of Hypertension in the Middle-Aged Prevent Dementia in the Elderly?. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 97-104.	2.2	8

#	ARTICLE	IF	CITATIONS
19	Awareness of Genetic Coronary Risk Score Improves Blood Pressure Control in Hypertensive Patients. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1226-1227.	0.6	2
20	Lifetime risk of stroke in young-aged and middle-aged populations. Journal of Hypertension, 2016, 34, 2333-2334.	0.5	0
21	Patr3n circadiano de la presi3n arterial yÂfunci3n cognitiva deÂpacientes deÂmediana edad conÂhipertensi3n esencial. Revista Espanola De Cardiologia, 2015, 68, 157-158.	1.2	1
22	Circadian Blood Pressure Pattern and Cognitive Function in Middle-aged Essential Hypertensive Patients. Revista Espanola De Cardiologia (English Ed), 2015, 68, 157-158.	0.6	4
23	Commentary: Frequent nut consumption protects against cardiovascular and cancer mortality, but the effects may be even greater if nuts are included in a healthy diet. International Journal of Epidemiology, 2015, 44, 1049-1050.	1.9	1
24	Beyond Subjective Cognitive Failures in Patients With Hypertension?. Hypertension, 2014, 64, 455-456.	2.7	1
25	Effects of Recombinant Human Erythropoietin on Resistance Artery Endothelial Function in Stage 4 Chronic Kidney Disease. Journal of the American Heart Association, 2013, 2, e000128.	3.7	27
26	Ambulatory Blood Pressure in Stroke and Cognitive Dysfunction. Current Hypertension Reports, 2013, 15, 150-159.	3.5	14
27	Urinary Albumin Excretion at Follow-Up Predicts Cardiovascular Outcomes in Subjects With Resistant Hypertension. American Journal of Hypertension, 2013, 26, 1148-1154.	2.0	11
28	Diabetes and Stroke Prevention: A Review. Stroke Research and Treatment, 2012, 2012, 1-6.	0.8	29
29	Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure. Blood Pressure, 2012, 21, 31-38.	1.5	67
30	Hypertension and Mild Cognitive Impairment. Current Hypertension Reports, 2012, 14, 548-555.	3.5	47
31	Associations between Ambulatory Blood Pressure Parameters and Cerebral White Matter Lesions. International Journal of Hypertension, 2011, 2011, 1-7.	1.3	20
32	Vascular Mechanisms in the Pathogenesis of Stroke. Current Hypertension Reports, 2011, 13, 200-207.	3.5	130
33	Connecting Cerebral White Matter Lesions and Hypertensive Target Organ Damage. Journal of Aging Research, 2011, 2011, 1-7.	0.9	18
34	Aldosterone Excess or Escape: Treating Resistant Hypertension. Journal of Clinical Hypertension, 2009, 11, 245-252.	2.0	25
35	The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension. Expert Review of Cardiovascular Therapy, 2008, 6, 1055-1062.	1.5	11
36	Early detection and management of the high-risk patient with elevated blood pressure. Vascular Health and Risk Management, 2008, Volume 4, 289-296.	2.3	27

#	ARTICLE	IF	CITATIONS
37	Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20 000-patient database in Spain. Journal of Hypertension, 2007, 25, 977-984.	0.5	102
38	Silent Cerebral Damage in Hypertension. Current Hypertension Reviews, 2007, 3, 83-88.	0.9	1
39	Reproducibility of the circadian blood pressure pattern in 24-h versus 48-h recordings: the Spanish Ambulatory Blood Pressure Monitoring Registry. Journal of Hypertension, 2007, 25, 2406-2412.	0.5	56
40	Increased Levels of Atherosclerosis Markers in Salt-Sensitive Hypertension. American Journal of Hypertension, 2006, 19, 87-93.	2.0	30
41	Relation of Left Ventricular Hypertrophy to Regional Cerebral Blood Flow: Single Photon Emission Computed Tomography Abnormalities in Essential Hypertension. Journal of Clinical Hypertension, 2006, 8, 700-705.	2.0	6
42	White Matter Lesions and Cognitive Impairment as Silent Cerebral Disease in Hypertension. Scientific World Journal, The, 2006, 6, 494-501.	2.1	18
43	Early brain damage in essential hypertension: “To have and have not” Is it important?. Current Hypertension Reports, 2006, 8, 269-270.	3.5	1
44	Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Current Opinion in Nephrology and Hypertension, 2005, 14, 435-441.	2.0	32
45	Nocturnal fall of blood pressure with antihypertensive therapy and recurrence of ischaemic stroke: “the lower the better” revisited. Journal of Hypertension, 2005, 23, 1131-1132.	0.5	5
46	Review: Role of the selective aldosterone receptor blockers in arterial hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, 23-25.	1.7	6
47	Cerebral hemodynamics and silent cerebral white matter lesions in middle-aged essential hypertensive patients. Blood Pressure, 2004, 13, 304-309.	1.5	53
48	Silent cerebral white matter lesions and cognitive function in middle-aged essential hypertensive patients*1. American Journal of Hypertension, 2004, 17, 529-534.	2.0	58
49	Increased serum markers of vascular inflammation in essential hypertensives patients with the dd genotype of the ace gene. American Journal of Hypertension, 2004, 17, S241.	2.0	0
50	Blood pressure variability and silent cerebral damage in essential hypertension. American Journal of Hypertension, 2004, 17, 696-700.	2.0	53
51	Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clinical Therapeutics, 2003, 25, 2849-2864.	2.5	29
52	New-onset diabetes and antihypertensive therapy: comments on ALLHAT trial. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 169-170.	1.7	16
53	Renin-Angiotensin System Genetic Polymorphisms and Cerebral White Matter Lesions in Essential Hypertension. Hypertension, 2002, 39, 343-347.	2.7	62
54	Silent cerebral white matter lesions in middle-aged essential hypertensive patients. Journal of Hypertension, 2002, 20, 519-524.	0.5	90

#	ARTICLE	IF	CITATIONS
55	Correlation between silent cerebral white matter lesions and left ventricular mass and geometry in essential hypertension. American Journal of Hypertension, 2002, 15, 507-512.	2.0	42
56	Effect of one year antihypertensive treatment on blood pressure variability in essential hypertensive patients with silent cerebral white matter lesions. preliminary results. American Journal of Hypertension, 2002, 15, A74.	2.0	0
57	Cerebral white matter lesions in essential hypertension. Current Hypertension Reports, 2001, 3, 429-433.	3.5	18
58	Effect of long-term antihypertensive therapy with angiotensin converting enzyme inhibitors on red cell sodium transport. American Journal of Hypertension, 1995, 8, 622-625.	2.0	7
59	Assessment of salt sensitivity in essential hypertension by 24-h ambulatory blood pressure monitoring*. American Journal of Hypertension, 1995, 8, 970-977.	2.0	59